A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2018

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 11 Jun 2018 Planned End Date changed from 12 May 2020 to 31 Dec 2020.
    • 11 Jun 2018 Planned primary completion date changed from 12 Dec 2018 to 30 Apr 2019.
    • 08 May 2018 According to a CymaBay Therapeutics media release, Stephen Harrison, MD, Medical Director of Pinnacle Clinical Research is the principal coordinating investigator for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top